We are live on ! Find out more
BMRN icon

BioMarin Pharmaceuticals
BMRN

449 hedge funds and large institutions have $17.2B invested in BioMarin Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 66 funds opening new positions, 167 increasing their positions, 138 reducing their positions, and 45 closing their positions.

New
Increased
Maintained
Reduced
Closed

56% more call options, than puts

Call options by funds: $180M | Put options by funds: $115M

47% more first-time investments, than exits

New positions opened: 66 | Existing positions closed: 45

33% more funds holding in top 10

Funds holding in top 10: 9 → 12 (+3)

21% more repeat investments, than reductions

Existing positions increased: 167 | Existing positions reduced: 138

18% more capital invested

Capital invested by funds: $14.6B → $17.2B (+$2.59B)

4% more funds holding

Funds holding: 430 → 449 (+19)

1.11% more ownership

Funds ownership: 102.41% → 103.52% (+1.1%)

Holders
449
Holders Change
+19
Holders Change %
+4.42%
% of All Funds
10.28%
Holding in Top 10
12
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+33.33%
% of All Funds
0.27%
New
66
Increased
167
Reduced
138
Closed
45
Calls
$180M
Puts
$115M
Net Calls
+$64.8M
Net Calls Change
+$86.2M

Top Buyers

Rank Fund Capital Flow
1
ClearBridge Investments
ClearBridge Investments
New York
+$197M
2
Ameriprise
Ameriprise
Minnesota
+$140M
3
Viking Global Investors
Viking Global Investors
Connecticut
+$138M
4
SIG
Senator Investment Group
New York
+$87.6M
5
PI
Putnam Investments
Massachusetts
+$45M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$178M
2
O
OppenheimerFunds
New York
-$94.9M
3
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans
Minnesota
-$77.9M
4
Invesco
Invesco
Georgia
-$77.3M
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$54.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
PAMU
26
Pictet Asset Management (UK)
United Kingdom
$136M -$10.3M -118,184 -8%
Bank of New York Mellon
27
Bank of New York Mellon
New York
$126M -$6.45M -73,623 -5%
HCM
28
Highline Capital Management
New York
$124M +$3.99M +45,550 +4%
FCM
29
Frontier Capital Management
Massachusetts
$114M +$31.7M +362,531 +43%
JP Morgan Chase
30
JP Morgan Chase
New York
$114M +$13.2M +151,058 +14%
Neuberger Berman Group
31
Neuberger Berman Group
New York
$112M +$41.3M +471,829 +66%
UBS AM
32
UBS AM
Illinois
$111M +$2.54M +28,971 +3%
Deutsche Bank
33
Deutsche Bank
Germany
$106M -$10.7M -121,859 -10%
UIM
34
USS Investment Management
United Kingdom
$105M -$20.1M -229,671 -17%
Northern Trust
35
Northern Trust
Illinois
$104M +$1.08M +12,326 +1%
TCIM
36
TIAA CREF Investment Management
New York
$100M -$30.6M -349,191 -25%
SIG
37
Senator Investment Group
New York
$94.2M +$87.6M +1,000,000 New
FAM
38
Fred Alger Management
New York
$91.8M +$3.49M +39,852 +4%
Massachusetts Financial Services
39
Massachusetts Financial Services
Massachusetts
$91.2M +$725K +8,282 +0.9%
Norges Bank
40
Norges Bank
Norway
$90.5M +$3.9M +44,480 +5%
Loomis, Sayles & Company
41
Loomis, Sayles & Company
Massachusetts
$88.7M +$6.19M +70,654 +8%
TG
42
TCW Group
California
$81.3M -$4.05M -46,268 -5%
Wells Fargo
43
Wells Fargo
California
$74.7M +$4.02M +45,881 +6%
First Trust Advisors
44
First Trust Advisors
Illinois
$66.3M +$7.66M +87,468 +14%
Legal & General Group
45
Legal & General Group
United Kingdom
$64.9M -$2.76M -31,546 -4%
Victory Capital Management
46
Victory Capital Management
Texas
$64.5M -$5.87M -67,070 -9%
TA
47
Teachers Advisors
New York
$61.6M +$143K +1,633 +0.3%
American Century Companies
48
American Century Companies
Missouri
$57M -$20.6M -235,479 -28%
Millennium Management
49
Millennium Management
New York
$55.5M -$4.88M -55,750 -9%
Morgan Stanley
50
Morgan Stanley
New York
$55.3M +$10.8M +123,430 +27%
1
2
3 4 5

BMRN Hedge Fund Activity: Q2 2018 in Review

449 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q2 2018, worth a combined $17.2B — up 18% from $14.6B a quarter earlier.

Buyers outnumbered sellers: 66 funds opened new BMRN positions and 45 closed out — a net gain of 21 holders — while 167 added to existing stakes and 138 trimmed.

The largest buyer was ClearBridge Investments, adding an estimated $197M. The largest seller was Fidelity Investments, cutting an estimated $178M.

  • 449 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q2 2018, up from 430 in Q1 2018.
  • Funds reported $17.2B of BioMarin Pharmaceuticals stock for Q2 2018, up 18% quarter-over-quarter.
  • 66 funds opened new BioMarin Pharmaceuticals positions in Q2 2018 and 45 closed out, a net change of +21 holders.
  • The largest BioMarin Pharmaceuticals buyer in Q2 2018 was ClearBridge Investments, an estimated $197M added.
  • The largest BioMarin Pharmaceuticals seller in Q2 2018 was Fidelity Investments, an estimated $178M sold.

Based on aggregated 13F filings for Q2 2018.